Pulmonx (LUNG) Reports $68.7M Revenue with 28% Growth and COPD Innovations
Pulmonx Corporation (LUNG), a leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), reported a record…
UroGen (URGN) Posts $25.2M Q3 Revenue, Targets $5B Market with UGN-102 Launch
UroGen Pharma Ltd. (URGN), a biotechnology company revolutionizing cancer care, announced Q3 2024 revenue of $25.2 million, a…
ABBV-RGX-314 Gene Therapy Reduces nAMD Injections in Bilateral Study
In a major advancement for treating neovascular age-related macular degeneration (nAMD), the investigational gene therapy ABBV-RGX-314 of Regenxbio…
Rigel (RIGL)’s Q3 2024 Revenue Hits $55.3M
Rigel Pharmaceuticals, Inc. (RIGL), a biotech leader in hematologic disorders and oncology, reported strong Q3 2024 financial growth…
Lakeside Holding (LSH) Acquires Hupan Pharmaceutical to Enter China’s Medical Logistics Market
Lakeside Holding Limited (LSH), a U.S.-based leader in cross-border supply chain solutions, has officially expanded into the medical…
Autolus (AUTL) Reports Obe-cel Launch Progress and Strong Cash Position in Q2 2024
Autolus Therapeutics plc (AUTL), a leader in T-cell therapies, announced its Q2 2024 financial results and business updates.…
FDA Clears CEL-SCI’s Multikine Study for Head and Neck Cancer
CEL-SCI Corporation (CVM), a leader in immunotherapy, announced FDA approval of its patient selection strategy for the upcoming…
Aethlon (AEMD) Reports Q1 2024 Results and Advances Cancer and Virus Treatment Trials
Aethlon Medical, Inc. (AEMD), a pioneering company in cancer and infectious disease therapies, has reported its fiscal Q1…
Treace Medical (TMCI) Reports 11% Revenue Growth in Q3 2024
Treace Medical Concepts, Inc. (TMCI), a leading innovator in the medical technology space focused on bunion treatment, announced…
Taysha Gene (TSHA) Reports Strong Q2 2024 Results and Advances TSHA-102 Trials
Taysha Gene Therapies, Inc. (TSHA), a leader in developing AAV-based gene therapies for severe central nervous system diseases,…
CEL-SCI’s Multikine Immunotherapy Boosts 5-Year Survival Rate in Head and Neck Cancer
CEL-SCI Corporation (NYSE American: CVM) has announced new breakthrough data from its Phase 3 trial of Multikine®, an…
Novartis Pioneers RNA Therapeutics with Borealis Biosciences for Kidney Diseases
Introduction In a groundbreaking move for the biotech industry, Novartis has partnered with Versant Ventures to establish Borealis…
Genentech’s Strategic Pivot: The Closure of Its Cancer Immunology Unit
Introduction In a significant and somewhat unexpected move within the biotech industry, Genentech, a subsidiary of Roche, has…
Breakthrough in Alzheimer’s Treatment: Biogen and Eisai’s Leqembi Wins UK Approval
Introduction The landscape of Alzheimer’s disease treatment has undergone a monumental shift with the UK’s Medicines and Healthcare…
Pioneering Cell & Exosome Therapies for Rare Diseases | Capricor Therapeutics Interview with Dr. Linda Marbán and AJ Bergmann
Join us on BioTech Health X as we sit down with Dr. Linda Marbán, CEO, and AJ Bergmann,…
The Future of Cell & Gene Therapy Logistics with Cryoport | Interview with CEO Mark Sawicki
In an exclusive interview with BioTech Health X host Allison Goodlove, Cryoport (NASDAQ: CYRX) President & CEO Mark…
Geert Kersten on CEL-SCI’s Multikine and the Future of Immunotherapy – Exclusive Interview
In this exclusive interview, host Allison Godlove sits down with CEL-SCI (NYSEAMERICAN: CVM) CEO Geert Kersten to delve…
Vera Therapeutics’ Atacicept Shows Promising Results in Phase 2b ORIGIN Trial for IgA Nephropathy
Vera Therapeutics has announced positive results from their Phase 2b ORIGIN clinical trial for atacicept, a novel investigational…